Chronic therapies and price increases drove 7.8 per cent growth in India's pharma market in April 2025, with cardiac and gastrointestinal segments showing double-digit value gains
But a fall in doctor visits hit acute therapy drugs. July saw a major turnaround
Top pharma companies will continue to face severe pricing pressure and regulatory overhang in FY18